Private equity player OrbiMed Advisors, which invests in the life science space, registered to raise a $300 million fund to invest in healthcare companies in Asia, according to an SEC filing.
OrbiMed’s Shanghai- and Mumbai-based Asia PE fund focuses on "opportunities in China and India across all sectors of healthcare, including healthcare services," according to its website.
OrbiMed Asia Partners II LP filed for the round August 14, listing Merrill Lynch, Pierce, Fenner & Smith Inc. as broker, according to the filing.
OrbiMed closed a $222 million fund aimed at the Israeli life science market in April 2012.
OrbiMed’s portfolio includes investments in medical device companies Acutus Medical, Bonovo Orthopedics, CardiAQ Valve Technologies, Cerapedics, DFine, China’s EA Inc., Glaukos, InspireMD, Insulet (NSDQ:PODD), Keystone Heart, Medigus, NxStage Medical (NSDQ:NXTM), OmniGuide, Ornim Medical, Realton Corp., Response BioMedical, Sientra, Sonendo, TELA Bio, ViewRay, Velico Medical and Whale Imaging.
And it was 1 of the investors behind superDimension, which Covidien (NYSE:COV) acquired for $300 million in March 2012.